Teleflex Misses Q4 Earnings Estimates, Announces Restructuring

Medical tech firm to sell several business units, use proceeds to repay debt and buy back shares

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Teleflex (NYSE:TFX), a medical technology company, reported its fourth-quarter earnings results, missing analysts' consensus estimates by $1.80 per share. The company posted earnings of $1.93 per share, well below the expected $3.73 per share. Revenue for the quarter was $569 million, down 28.5% year-over-year and significantly lower than the expected $912.57 million.

Why it matters

Teleflex's disappointing earnings and revenue results, along with its reduced full-year 2026 guidance, suggest the company is facing significant headwinds. The planned divestitures and restructuring efforts indicate Teleflex is looking to streamline its operations and focus on its core business segments, which could help improve profitability in the long run.

The details

Teleflex announced it has signed definitive agreements to sell its Acute Care, Interventional Urology, and OEM businesses for a total of $2.03 billion in cash proceeds (approximately $1.8 billion after tax). The company intends to use the proceeds to repurchase up to $1 billion of its shares and pay down around $800 million of debt. Additionally, Teleflex approved a restructuring plan to rightsize the organization and mitigate stranded costs, targeting about $50 million in annual pre-tax savings to be substantially completed by mid-2028.

  • Teleflex reported its Q4 2025 earnings results on Thursday, February 28, 2026.
  • The planned divestitures are expected to close in the second half of 2026.
  • The restructuring plan is expected to be substantially completed by mid-2028.

The players

Teleflex

A diversified global provider of medical technologies, specializing in critical care and surgery.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Teleflex's restructuring and portfolio optimization efforts are aimed at simplifying its business, reducing costs, and improving profitability, but the company faces a challenging transition period in 2026 before expected earnings improvement in 2027.